International Clinical Trial: A Phase 1a/b Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study with an Open-Label Active-Controlled Phase, to Evaluate the Safety and Immunogenicity of Centi-Flu 01 in Healthy Adults 18 Years of Age and Older

Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ACTRN12626000259347) titled 'A Phase 1a/b Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study with an Open-Label Active-Controlled Phase, to Evaluate the Safety and Immunogenicity of Centi-Flu 01 in Healthy Adults 18 Years of Age and Older' on March 2.

Study Type: Interventional

Study Design: Purpose: Prevention Allocation: Randomised controlled trial

Primary Sponsor: Centivax, Inc.

Condition: Influenza Influenza Respiratory - Other respiratory disorders / diseases

Intervention: This is a double-blind, placebo-controlled, dose-escalating study conducted in healthy adult volunteers. The study will be conducted in 2 ...